Mitochondrial DNA Heteroplasmy Sets a Metabolic Rheostat for Nuclear Chromatin State via Acetyl-CoA and NAD+-Dependent Enzymes

Hypothesis The burden of mitochondrial DNA (mtDNA) heteroplasmy dictates nuclear chromatin organization not only through acetyl‑CoA supply but also by shifting the NAD⁺/NADH ratio, thereby tuning the activity of sirtuins and TET enzymes. This dual metabolic rheostat links mtDNA integrity to both histone acetylation and DNA methylation, creating a coordinated epigenetic aging program.

Mechanistic Rationale

1. Acetyl‑CoA axis – As shown, pathogenic mtDNA mutations curb glucose‑derived acetyl‑CoA, limiting substrate for histone acetyltransferases (HATs) and causing global hypoacetylation (e.g., H4K12ac, H3K9ac) 1.
2. NAD⁺/NADH axis – Defective oxidative phosphorylation raises NADH and lowers NAD⁺, diminishing SIRT1 deacetylase activity. SIRT1 also activates ACSS2, the acetate‑to‑acetyl‑CoA conduit, and deacetylates H3K9ac at promoters of pro‑longevity genes (e.g., TFEB targets) 5. A low NAD⁺/NADH ratio therefore blunts this compensatory pathway.
3. DNA methylation axis – The TET family of dioxygenases requires α‑ketoglutarate and is inhibited by succinate, both of which fluctuate with TCA cycle flux driven by mitochondria. Elevated succinate from defective OXPHOS suppresses TET activity, reducing 5‑hydroxymethylcytosine (5hmC) and promoting promoter methylation of mitochondrial‑nuclear communication genes.

Integrative Model High mtDNA heteroplasmy → ↓ acetyl‑CoA + ↑ NADH/↓ NAD⁺ + ↑ succinate → (a) HAT substrate loss → histone hypoacetylation; (b) SIRT1 inhibition → reduced ACSS2 activation and loss of deacetylation‑dependent gene activation; (c) TET inhibition → DNA hypermethylation → silencing of nuclear genes that sustain mitochondrial biogenesis (e.g., PGC‑1α, NRF1). This creates a feed‑forward loop where nuclear gene expression fails to rescue mitochondrial function, accelerating aging.

Testable Predictions

• Prediction 1: In cybrid cell lines with graded mtDNA heteroplasmy, nuclear acetyl‑CoA levels will correlate inversely with heteroplasmy load, while NAD⁺/NADH ratio will show a reciprocal trend.
• Prediction 2: Global H4K12ac and H3K9ac will decline with heteroplasmy, but SIRT1‑dependent deacetylation of specific loci (e.g., TFEB promoters) will be disproportionately lost due to NAD⁺ depletion.
• Prediction 3: 5hmC levels will drop as heteroplasmy rises, reflecting succinate‑mediated TET inhibition.
• Prediction 4: Supplementation with acetate (to boost ACSS2) or NAD⁺ precursors (e.g., NR) will partially restore histone acetylation and 5hmC only when SIRT1 is present; SIRT1 knockout will abolish rescue.
• Prediction 5: Overexpressing ACSS2 in high‑heteroplasmy cells will rescue histone acetylation but not DNA methylation, indicating that the two arms are separable.

Experimental Design

1. Generate ρ⁰ cells repopulated with mtDNA carrying defined heteroplasmy percentages of a pathogenic mutation (e.g., m.3243A>G).
2. Quantify nuclear acetyl‑CoA (LC‑MS), NAD⁺/NADH ratio, succinate, global histone acetylation (Western blot for H4K12ac, H3K9ac), and 5hmC (dot‑blot or ELISA).
3. Treat subsets with acetate (10 mM), nicotinamide riboside (1 mM), or both, ± SIRT1 inhibitor (EX‑527) or ACSS2 siRNA.
4. Assess rescue of acetylation, 5hmC, and expression of mitochondrial‑nuclear genes (qPCR, RNA‑seq).
5. Perform CRISPR‑based mtDNA editing to lower heteroplasmy and confirm reversal of metabolic and epigenetic marks.

Falsifiability If restoring nuclear acetyl‑CoA via ACSS2 overexpression fully normalizes both histone acetylation and DNA methylation despite persistent high mtDNA heteroplasmy and altered NAD⁺/NADH ratios, the hypothesis that mtDNA drives aging through this dual metabolic rheostat would be falsified. Conversely, if epigenetic defects persist despite acetyl‑CoA rescue but are alleviated by NAD⁺ restoration, the model gains support.

Implications This framework positions mtDNA not merely as a passive supplier of acetyl‑CoA but as a central regulator of nuclear chromatin through interconnected metabolite‑sensitive enzymes. Longevity interventions that target only one arm (e.g., acetate supplementation) may fail unless the NAD⁺/NADH and TET/succinate axes are also addressed.